These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1649 related items for PubMed ID: 24121489

  • 1. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 2. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
    Wang AX, Qi XY.
    IUBMB Life; 2013 Sep 01; 65(9):748-58. PubMed ID: 23893853
    [Abstract] [Full Text] [Related]

  • 3. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM.
    Biochem Pharmacol; 2015 May 01; 95(1):16-27. PubMed ID: 25795251
    [Abstract] [Full Text] [Related]

  • 4. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.
    Hong SP, Ahn SK.
    Life Sci; 2017 Aug 15; 183():37-44. PubMed ID: 28645859
    [Abstract] [Full Text] [Related]

  • 5. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
    Shao W, Mishina YM, Feng Y, Caponigro G, Cooke VG, Rivera S, Wang Y, Shen F, Korn JM, Mathews Griner LA, Nishiguchi G, Rico A, Tellew J, Haling JR, Aversa R, Polyakov V, Zang R, Hekmat-Nejad M, Amiri P, Singh M, Keen N, Dillon MP, Lees E, Ramurthy S, Sellers WR, Stuart DD.
    Cancer Res; 2018 Mar 15; 78(6):1537-1548. PubMed ID: 29343524
    [Abstract] [Full Text] [Related]

  • 6. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM, Simeone E, Festino L, Vanella V, Palla M, Ascierto PA.
    Discov Med; 2015 Jun 15; 19(107):455-61. PubMed ID: 26175403
    [Abstract] [Full Text] [Related]

  • 7. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M, Voit C.
    Crit Rev Oncol Hematol; 2013 Sep 15; 87(3):239-55. PubMed ID: 23415641
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors.
    Basile KJ, Le K, Hartsough EJ, Aplin AE.
    Pigment Cell Melanoma Res; 2014 May 15; 27(3):479-84. PubMed ID: 24422853
    [Abstract] [Full Text] [Related]

  • 9. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M, Getz G, Dias-Santagata D, Iafrate AJ, Engelman JA, Garraway LA, Corcoran RB.
    Cancer Discov; 2015 Apr 15; 5(4):358-67. PubMed ID: 25673644
    [Abstract] [Full Text] [Related]

  • 10. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS, Jung M, Kang HN, Kim H, Park CW, Kim SM, Shin SJ, Kim SH, Kim SG, Kim EK, Yun MR, Zheng Z, Chung KY, Greenbowe J, Ali SM, Kim TM, Cho BC.
    Oncogene; 2017 Jun 08; 36(23):3334-3345. PubMed ID: 28092667
    [Abstract] [Full Text] [Related]

  • 11. Metastatic Melanoma Patient-Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition.
    Shattuck-Brandt RL, Chen SC, Murray E, Johnson CA, Crandall H, O'Neal JF, Al-Rohil RN, Nebhan CA, Bharti V, Dahlman KB, Ayers GD, Yan C, Kelley MC, Kauffmann RM, Hooks M, Grau A, Johnson DB, Vilgelm AE, Richmond A.
    Clin Cancer Res; 2020 Jul 15; 26(14):3803-3818. PubMed ID: 32234759
    [Abstract] [Full Text] [Related]

  • 12. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, Pinheiro EM, Koya RC, Graeber TG, Comin-Anduix B, Ribas A.
    Sci Transl Med; 2015 Mar 18; 7(279):279ra41. PubMed ID: 25787767
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.
    J Clin Oncol; 2013 May 10; 31(14):1767-74. PubMed ID: 23569304
    [Abstract] [Full Text] [Related]

  • 14. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C, Egyhazi Brage S.
    Pharmacol Ther; 2014 May 10; 142(2):176-82. PubMed ID: 24325952
    [Abstract] [Full Text] [Related]

  • 15. The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells.
    Wada M, Horinaka M, Yamazaki T, Katoh N, Sakai T.
    PLoS One; 2014 May 10; 9(11):e113217. PubMed ID: 25422890
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C.
    Mol Cancer; 2017 Jun 08; 16(1):102. PubMed ID: 28595656
    [Abstract] [Full Text] [Related]

  • 19. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE.
    Matrix Biol; 2015 Oct 08; 48():66-77. PubMed ID: 25989506
    [Abstract] [Full Text] [Related]

  • 20. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA, Lin L, Olivas V, Chan E, Markegard E, Rymar A, Neel D, Chen X, Hemmati G, Bollag G, Bivona TG.
    Proc Natl Acad Sci U S A; 2016 Nov 22; 113(47):13456-13461. PubMed ID: 27834212
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 83.